Leerink Partners Reiterates Buy Rating on RGNX
Leerink Partners maintains a buy rating on RGNX with an $18 price target, a 130.77% upside from the current price.
Key Points
- On June 22, 2026, Leerink Partners reiterated its buy rating on RGNX with a price target of $18.
- Leerink Partners's $18 price target implies 130.77% upside from REGENXBIO Inc.'s ($RGNX) current $7.80 share price.
- RGNX shares traded near $7.80 on Monday, with recent insider buying activity reported at the company.
- Other analysts, including Baird and HC Wainwright & Co., also maintain buy ratings on RGNX with varied price targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Leerink Partners reiterated its buy rating on RGNX, setting a price target of $18. This update comes as the stock traded around $7.80 on Monday.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in RGNX
BlackRock, Inc. grew its holdings by 25,997 shares, ending with 5,782,808 shares worth about $48.5 million. State Street Corp increased its position by 444,749 shares, bringing its total to 2,731,485 shares valued at approximately $22.9 million, marking a 19.4% increase. Meanwhile, JPMorgan Chase & Co reduced its stake by 69,702 shares to 3,483,800 shares, valued at $27.1 million, a 2.0% decrease.
REGENXBIO Inc. Stock Down 19.3%
Shares of RGNX traded near $7.80 on Monday. The company has seen significant insider buying activity recently, which might be of interest to investors tracking insider sentiment.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at REGENXBIO Inc.
On May 29, 2026, several insiders, including Daniel Tasse, Kenneth Mills, and David Stump, purchased 46,600 shares each. Additional purchases were made by Kenneth Mills, Allan Fox, and Alexandra Glucksmann, who each acquired 9,807 shares on the same date.
Analysts Set New Price Targets
On June 22, 2026, Baird maintained its buy rating on RGNX with a $32 price target. Leerink Partners reiterated its buy rating with an $18 target. Earlier, on June 5, 2026, HC Wainwright & Co. maintained their buy rating with a $26 price target. The consensus among analysts suggests a strong buy rating for RGNX, highlighting a favorable outlook.
Bottom Line
Leerink Partners' reiterated buy rating on RGNX with an $18 target highlights ongoing confidence in the company's potential. The stock's recent trading price of $7.80 and insider buying activity may be noteworthy for investors. It's essential to remember that analyst ratings are based on past data and may not reflect current market conditions.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.